Twist Bioscience Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Twist Bioscience Corporation
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
- Research, Analytical Equipment & Supplies
- Artificial Intelligence
- Antisense, Oligonucleotides
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Other Names / Subsidiaries
- Genome Compiler Corporation, Twist Biopharma
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.